TriSalus Reports Q4 and Full Year 2023 Financial Results and

Reported revenues of $5.7 million in 4Q23, up 77% over prior year



Full year revenues of $18.5 million, up 49% over prior year



Gross Margin of 90% in 4Q23 and 86% for full year



CMS...

Related Keywords

Texas , United States , Mary Szela , Intrahepatic Cholangiocarcinoma , Trisalus Life Sciences , Centers For Medicare Medicaid Services , Linkedin , Academic Oncology Centers , University Of Texas Md Anderson Cancer Center , Nasdaq , Company Annual Report On Form , Twitter , Technology Healthcare Common Procedure Coding System , Exchange Commission , Trisalus Life Sciences Inc , Society For Immunotherapy , Current Medical Research , Chief Executive Officer , Trinav Infusion System , Medicaid Services , Trinav Infusion , Ambulatory Payment Classification , World Data Demonstrates Ability , Successfully Treat Patients , Higher Disease Burden , Improve Delivery , Pressure Enabled Drug Delivery , Multiple Phase , Uveal Melanoma Liver Metastases , Hepatocellular Cancer , Leading Academic Oncology Centers Across , Determine Which Indication , Full Data Set Will , Second Half , Cancer Center , Novel Pancreatic Infusion , Pancreatic Infusion System , Trinav Large , Financial Results , Full Year , Late Filing , Annual Report , Infusion System , Pancreatic Retrograde Venous Infusion System , Pressure Enabled Regional Immuno Oncology , Private Securities Litigation Reform Act , Balance Sheets , Stockholder Equity ,